AnPac Bio-Medical Science (ANPC) Stock Climbs On COVID-19 News

AnPac Bio-Medical Science ANPC Stock News

AnPac Bio-Medical Science Co Ltd – ADR (NASDAQ: ANPC) stock is making a run for the top in the market this morning, and for good reason. The company announced news surrounding its efforts in the fight against the COVID-19 pandemic, exciting investors. Here’s what’s going on:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

ANPC Stock Rockets On COVID-19 News

In a press release issued in the premarket hours AnPac Bio-Medical Sciences said that the Company’s investee company in China, Jiangsu AnPac Health Management, qualified for COVID-19 nucleic acid tests in the first half of 2020 and received certification from the regulatory authority on October 17, 2020.

The certification surrounds COVID-19 nucleic acid tests, which will take place in the Jiangsu AnPac medical lab. In the release, ANPC said that it has already begun to receive samples for paid COVID-19 nucleic acid tests. Moreover, the company said that it has signed an agreement to develop and qualify new COVID-19 test technologies and products.

This work adds to the company’s novel cancer screening technology, products, and services. However, with COVID-19 cases rising again, the company is focused on testing opportunities and commercializing their COVID-19 products in the United States and China.

In a statement, Dr. Chris Yu, CEO at ANPC, had the following to offer:

In addition to a successful launch of our immunology test product in the first half year, the qualification and commercialization of COVID-19 tests is another major achievement for AnPac Bio this year. With the addition of above mentioned new products and services, and our novel, biophysics based cancer differentiation analysis (CDA) cancer screening tests, AnPac Bio is poised to offer our customers and market a much broader set of products and services and will contribute to our revenue growth significantly in the next few years.

This Is Big News

The news released by AnPac Bio-Medical Science proved to be overwhelmingly positive. As mentioned above, COVID-19 case counts are climbing. While the world awaits a vaccine and potential treatment options, testing is taking center stage in an attempt to keep the virus at bay.

Even when a vaccine and treatments become available, COVID-19 is likely to remain a big fear among consumers. Any time the average person comes down with the common cold, the thought of the pandemic will come to mind and they will likely seek testing. Ultimately, COVID-19 testing is a long-term market, and ANPC stock is one to watch as it works to commercialize testing in the United States and China.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don't MIss The Next Big Story

Join our free mailing list below to receive real-time news alerts!

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.